An exploratory analysis of the dutch pharmaceutical supply chain

Research output: Chapter in Book / Report / Conference proceedingConference contributionProfessional


The outbreak of the COVID-19 pandemic challenged
the Dutch pharmaceutical supply chain (PSC)
and required tremendous creativity and effort
from PSC partners to guarantee the availability
of drugs in the Netherlands and, consequently,
Dutch patients’ well-being. At the same time, the
COVID-19 pandemic exposed and compounded
existing issues and vulnerabilities in the Dutch PSC.
This report presents an exploratory analysis of the
structure of the Dutch PSC. Insights were gathered
from the literature and a series of interviews were
conducted with key PSC actors in the Netherlands.
We identify the current challenges and solutions
provided by different supply chain actors and extract
and analyze dependencies and vulnerabilities that
could compromise its efficiency and robustness. The
main results indicate that the Dutch PSC is part of
various international PSCs. Therefore, it is exposed
to several demand and supply characteristics and
vulnerabilities that also affect other countries.
Simultaneously, the regulation and specific
organization of the Dutch pharmaceutical sector has
a significant impact on national supply and demand
dynamics and how the Dutch PSC can be managed.
This report wants to shed light on these issues and
provide guidelines to further improve the PSC’s
Keywords: Pharmaceutical supply chain, incentives,
vulnerability, drug availability and shortages
Original languageEnglish
Title of host publicationDinalog
Publication statusPublished - 22 Jan 2021

Bibliographical note


  • Pharmaceutical supply chain
  • shortages
  • incentives
  • vulnerability
  • drug availability


Dive into the research topics of 'An exploratory analysis of the dutch pharmaceutical supply chain'. Together they form a unique fingerprint.

Cite this